All In Biotech

Drug Trial Radar · NCT06561607

A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

A Randomized, Open, Parallel-Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 542 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

542

Planned (sponsor's estimate)

Start

Oct 11, 2024

Primary completion

Jan 2027

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Aug 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a Phase III, randomized, multicenter, open-label study in HER2-low, HR+ metastatic breast cancer subjects who are patients with locally advanced or metastatic breast cancer with low HER2 expression in the recurrent metastatic stage who have not received chemotherapy. The primary objective of the study is to determine the efficacy and safety of TQB2102 compared to investigator-selected single-agent chemotherapy in the target population. 542 subjects with HER2 immunohistochemistry (IHC )2+/ in situ hybridization (ISH)- and IHC 1+ (HER2-low) expression will be enrolled in 1:1 randomized groups to receive TQB2102 or investigator's choice of single-agent chemotherapy (capecitabine, paclitaxel, or albumin-paclitaxel) until progression of disease (PD), as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1. 1, unless there are unacceptable toxicity, withdrawal of consent, or meeting other discontinuation criteria.

Conditions

  • Breast Cancer

Interventions

  • TQB2102 for InjectionDrug

    TQB2102 is a next-generation HER2 Antibody-Drug Conjugate (ADC) drug proposed for patients with HER2 low-expressing breast cancer.

  • Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)Drug

    Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs for treatment. * Capecitabine: 1000-1250 mg/m2 twice daily, administered consecutively on day 1-14, 21 days as a treatment cycle. * Paclitaxel: 175 mg/m2, IV infusion, administered Day1 per cycle, 21 days as a treatment cycle. OR 80 mg/m2 by IV infusion administered weekly. * Albumin Paclitaxel: 260 mg/m2, IV infusion, administered every cycle of Day1 for 21 days as a treatment cycle. 100 mg/m2 or 125 mg/m2, IV infusion, administered every cycle of Day 1 and Day 8 for 21 days as a treatment cycle; or Day 1, Day 8, and Day 15 administered every cycle for 28 days as a treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer as assessed by Independent Review Committee (IRC)Time frame: Up to 25 months

Locations

34 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China

  • AnHui Province Hospital West District

    Hefei, Anhui, China

  • The first Affiliated hospital of anhui medical university

    Hefei, Anhui, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Fujian Medical University 2nd Affiliated Hospital

    Quanzhou, Fujian, China

  • Zhangzhou Hospital in Fujian Province

    Zhangzhou, Fujian, China

  • Gansu Provincial Hospital

    Lanzhou, Gansu, China

  • Gansu Provincial Cancer Hospital

    Lanzhou, Gansu, China

  • Gansu Wuwei Tumour Hospital

    Wuwei, Gansu, China

  • Sun Yet-Sen University Cancer Certer

    Guangzhou, Guangdong, China

  • Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, China

  • Guigang City People'S Hospital

    Guigang, Guangxi, China

  • Cancer Hospital Affiliated to Guangxi Medical University

    Nanning, Guangxi, China

  • The First affiliated hospital of GuangXi medical university

    Nanning, Guangxi, China

  • The Affiliated Cancer Hospital of Guizhou Medical University Co., LTD

    Guiyang, Guizhou, China

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, China

  • The First Affiliated Hospital of Hainan Medical College

    Haikou, Hainan, China

  • Hainan General Hospital

    Haikou, Hainan, China

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China

  • Chengde Central Hospital

    Chengde, Hebei, China

  • Affiliated Cancer Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • AnYang Tumor Hospital

    Anyang, Henan, China

  • Henan Cancar Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Henan University of Science & Technology

    Luoyang, Hennan, China

  • Tongji Hospital Tongji Medical College of HUST

    Wuhan, Hubei, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Chifeng Municipal Hospital

    Chifeng, Inner Mongolia, China

  • The Second Hospital of DALIAN Medical University

    Dalian, Liaoning, China

  • Binzhou Medical College Affiliated Hospital

    Binzhou, Shandong, China

  • Binzhou People's Hospital

    Binzhou, Shandong, China

  • Obstetrics & Gynecology Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

  • Baoji Central Hospital

    Baoji, Shanxi, China

  • Affiliated Hospital of North Scichuan Medical College

    Nanchong, Sichuan, China

  • Affiliated Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.